Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only tools for early detection are based on radiological tests, some authors focused on serum markers (i.e., mesothelin). The aim of this study was the evaluation of new serum biomarkers to be used individually or in combination, in order to improve the outcome of patients whose disease would be diagnosed at an earlier stage. Serum and plasma were available from 43 subjects previously exposed to asbestos and 27 MPM patients, all being epithelioid type. All the new markers found differentially expressed in MPM and healthy subjects, by proteomic and genomic approaches, have been validated in the serum by the use of specific ELISA. The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to the identification of new serum markers in the diagnosis of MPM. These results, if confirmed in a larger series, may have a strong impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease and the clinical approach to an individualized therapy.

A Novel Panel of Serum Biomarkers for MPM Diagnosis

BONOTTI, ALESSANDRA;FODDIS, RUDY;LANDI, STEFANO;MELAIU, OMBRETTA;DE SANTI, CHIARA;GIUSTI, LAURA;DONADIO, ELENA;CIREGIA, FEDERICA;MAZZONI, MARIA ROSA;LUCACCHINI, ANTONIO;CRISTAUDO, ALFONSO
2017

Abstract

Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only tools for early detection are based on radiological tests, some authors focused on serum markers (i.e., mesothelin). The aim of this study was the evaluation of new serum biomarkers to be used individually or in combination, in order to improve the outcome of patients whose disease would be diagnosed at an earlier stage. Serum and plasma were available from 43 subjects previously exposed to asbestos and 27 MPM patients, all being epithelioid type. All the new markers found differentially expressed in MPM and healthy subjects, by proteomic and genomic approaches, have been validated in the serum by the use of specific ELISA. The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to the identification of new serum markers in the diagnosis of MPM. These results, if confirmed in a larger series, may have a strong impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease and the clinical approach to an individualized therapy.
Bonotti, Alessandra; Foddis, Rudy; Landi, Stefano; Melaiu, Ombretta; DE SANTI, Chiara; Giusti, Laura; Donadio, Elena; Ciregia, Federica; Mazzoni, MARIA ROSA; Lucacchini, Antonio; Bovenzi, M.; Comar, M.; Pantani, E.; Pistelli, A.; Cristaudo, Alfonso
File in questo prodotto:
File Dimensione Formato  
DM2017-3510984.pdf

accesso aperto

Descrizione: Testo completo
Tipologia: Versione finale editoriale
Licenza: Creative commons
Dimensione 523.43 kB
Formato Adobe PDF
523.43 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/853043
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact